OncoSolid™ Lung Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Lung Cancer Organoid Models

Lung cancer is the most mortality human cancer around the world and shows great diversity in genetic and histological features among individual populations. Organoids have sprung up as the most proper 3D model to accurately recapitulate human tumor biology and facilitate the study of immuno-oncology. Creative Biolabs is a leading service provider in organoid technology and CAR-T development, and we provide an optimal culture system, especially for lung cancer organoid generation and maintenance. Furthermore, we offer a sufficient characterization of the established organoids compared with parental tumors.

Fig.1 Illustrative cultivation steps for lung cancer organoid. (Ma, et al., 2022)

Workflow for Lung Cancer Organoid Generation

Lung cancer organoids can be established in three typical approaches, including:

Matrigel-based method
Air liquid interface (ALI) system
Microfluidic 3D system

Characterization of the Established Organoids

The organoid of lung cancer can be characterized using versatile methods in 3 aspects, including histomorphology, tumor marker identification, and genetic alterations.

Histomorphology H&E staining Bright-field microscopy Major structure of organoids Morphology of the cells

Tumor Marker ldentification Immunohistochemistry (IHC) Cell differentiation protein T umor markers

Genetic Alterations Whole exome sequencing (WES) Gene expression level Copy number variations (CNV), Mutated gene profile

Key Features of Our Lung Cancer Organoid Models

Different formulations and concentrations of growth factors are attempted for optimal cultivation.
Culture systems are optimized for each type of lung cancer organoids establishment.
Avoid the growth of normal cells adjacent to tumor cells.
A biobank organoids of multiple lung cancer types, including LUAD, LUSC, NSCLC, LCNEC, SCLC, and PC.
Both short-term culture and long-term culture organoids are available.

Related Lung Cancer CAR-T Products and Services

With extensive experience in CAR-T therapy development, Creative Biolabs provides lung cancer-targeted CAR-T-related products for in vitro anti-tumor efficacy tests. We also offer customized one-stop CAR-T development services for lung cancer studies.

Target antigen	Target description	CAR-T Products
OR2H1	OR2H1, an olfactory receptor, is expressed in multiple cancers but rarely expressed in normal tissues, which serves as a potential target for CAR-T therapies.	Anti-OR2H1 CAR-T
PSCA	PSCA, defined as prostate stem cell antigen, is overexpressed in multiple tumors, including prostate cancer and lung cancer.	Anti-PSCA CAR-T
Mesothelin	Mesothelin is a diagnostic target as well as an attractive target for immunotherapies.	Anti-Mesothelin CAR-T
EGFR	EGFR is one of the membrane proteins that has increased expression in lung cancer tissue.	Anti-EGFR CAR-T
MUC1	The expression of MUC1(Mucin 1) is significantly elevated than normal tissue cells and promotes tumor metastasis.	Anti-MUC1 CAR-T
CEA	CEA has an aberrant expression in lung cancer tissues and is an indicator of poor survival.	Anti-CEA CAR-T

Case Study

Lung Cancer Organoids Derived from Patient Tumor Tissue
Key Findings	Different types of lung cancers are used to establish organoids with varied success rates. Lung cancer organoids recapitulate the features of the parental tumor tissues in histology and genetics.
Representative Results	Fig.2 Lung cancer organoids retain the histological characteristics of separate initial tumor tissue validated by H&E staining and IHC analysis. (Kim, et al., 2019)

Experienced experts at Creative Biolabs offer premium quality organoids for the evaluation of CAR-T efficacy. We promise high quality and efficiency. Please contact us and get more detailed information.

References

Ma, H. C.; et al. Lung cancer organoids, a promising model still with long way to go. Critical reviews in oncology/hematology. 2022, 171: 103610.
Kim, M.; et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019, 10: 3991.